ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: LON:RENE
- CUSIP: N/A
- Web: N/A
- Market Cap: £64.08 million
- Outstanding Shares: 3,164,618,000
- 50 Day Moving Avg: GBX 2.19
- 200 Day Moving Avg: GBX 2.49
- 52 Week Range: GBX 2 - GBX 3.71
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
- Annual Revenue: $574,000.00
- Price / Sales: 111.64
- Book Value: GBX 0.02 per share
- Price / Book: 1.07
- Average Volume: 2.64 million shs.
Frequently Asked Questions for ReNeuron Group Plc (LON:RENE)
What is ReNeuron Group Plc's stock symbol?
ReNeuron Group Plc trades on the London Stock Exchange (LON) under the ticker symbol "RENE."
Where is ReNeuron Group Plc's stock going? Where will ReNeuron Group Plc's stock price be in 2017?
2 brokers have issued 1 year price objectives for ReNeuron Group Plc's shares. Their predictions range from GBX 9 to GBX 15. On average, they anticipate ReNeuron Group Plc's share price to reach GBX 12 in the next twelve months. View Analyst Ratings for ReNeuron Group Plc.
Who are some of ReNeuron Group Plc's key competitors?
Some companies that are related to ReNeuron Group Plc include Carr's Group PLC (CARR), Conygar Investment Company PLC (CIC), Green Dragon Gas (GDG), Redcentric PLC (RCN), Gem Diamonds Limited (GEMD), Avation PLC (AVAP), Carr's Group PLC (CRM), MaxCyte (MXCT), Wynnstay Group plc (WYN), Inland Homes PLC (INL), Berkeley Energia Ltd (BKY), Mariana Resources (MARL), Cello Group plc (CLL), Hansard Global plc (HSD), Wireless Group PLC (UTV), Churchill China plc (CHH), Moss Bros Group plc (MOSB) and Real Estate Investors PLC. (RLE).
How do I buy ReNeuron Group Plc stock?
Shares of ReNeuron Group Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
How much does a share of ReNeuron Group Plc stock cost?
One share of ReNeuron Group Plc stock can currently be purchased for approximately GBX 2.03.
Consensus Ratings for ReNeuron Group Plc (LON:RENE) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 12|
Analysts' Ratings History for ReNeuron Group Plc (LON:RENE)
(Data available from 5/23/2015 forward)
|4/27/2017||N+1 Singer||Reiterated Rating||Buy||GBX 9|
|4/4/2017||Stifel Nicolaus||Reiterated Rating||Buy||GBX 15|
Earnings History for ReNeuron Group Plc (LON:RENE)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for ReNeuron Group Plc (LON:RENE)
Current Year EPS Consensus Estimate: $-0.730 EPS
Dividend History for ReNeuron Group Plc (LON:RENE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ReNeuron Group Plc (LON:RENE)Insider Trades by Quarter for ReNeuron Group Plc (LON:RENE)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/7/2017||Michael Hunt||Insider||Buy||250,000||GBX 3||£7,500|
|2/2/2016||Edward Berriman,John||Insider||Buy||318,476||GBX 3||£9,554.28|
|1/29/2015||Olav Hellebø||Insider||Buy||322,778||GBX 3.10||£10,006.12|
Headline Trends for ReNeuron Group Plc (LON:RENE)
Latest Headlines for ReNeuron Group Plc (LON:RENE)
ReNeuron Group Plc (RENE) Chart for Tuesday, May, 23, 2017